arrow
H

Harshabad Singh

Harvard University
H指数:19
被引数:1,527

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trial

奥拉帕尼与尼沃鲁单抗联合治疗微卫星稳定型结直肠癌:一项1/2期临床试验

2026-07-230
OA
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial

吉西他滨和nab-紫杉醇联合或不联合VDR激动剂帕立骨化醇治疗转移性胰腺癌: 一项随机,多臂,磨合期试验

2026-05-250
PRE
Pancreatic Reirradiation: A Multi-Institutional Retrospective Analysis of Feasibility, Tolerability, and Clinical Outcomes

胰腺再放疗:一项多机构回顾性分析可行性、耐受性及临床结局

2026-01-010
PRE
Integrative genomic identification of therapeutic targets for pancreatic cancer

整合基因组学鉴定胰腺癌的治疗靶点

2025-08-210
PREAI
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
2024-09-160
PRE
Phase 2 Trial Testing The PARP Inhibitor Niraparib In Patients With Advanced Pancreatic Cancer with Pathogenic Variants In BRCA 1, BRCA2, PALB2, ATM and CHEK2
2024-09-150
PRE
Temporal stability and chemotherapy responsiveness of classical and basal transcriptional subtypes of pancreatic cancer
2024-09-150
PRE
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+gastroesophageal adenocarcinoma
2024-08-091
OAAI
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting (vol 8, 87, 2024)
2024-05-060
OAAI
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
2024-04-082
OAAI
RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
2024-02-121
PRE
A phase 1 expansion cohort study evaluating the safety and efficacy of the CHK1 inhibitor LY2880070 with low-dose gemcitabine in metastatic pancreatic adenocarcinoma
2024-01-160
PRE